Project Grant HT94252310582
Award Date
7/15/23
Completion Date
7/14/25
Dollars Obligated
$630K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
The federal Project Grant award of $1,317,976.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, is supporting research at The Ohio State University to target RAL G proteins in the treatment of triple-negative breast cancer. The award, effective July 1, 2025 through June 30, 2028, will fund advanced biomedical research focused on developing innovative approaches to disease prevention, diagnosis, and treatment for conditions...
The federal Project Grant award of $1,574,999.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced research at The Ohio State University aimed at developing a novel approach for targeting metastatic breast cancer. The project, titled "SLIT2 AS A NOVEL APPROACH FOR TARGETING METASTATIC BREAST CANCER," focuses on investigating the potential of the SLIT2 protein as a therapeutic target for treating metastatic breast...
This federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $551,250.00 to The Ohio State University to support research on PPP2R1B IN DEDIFFERENTIATED LIPOSARCOMA. The project will be performed in Columbus, OH and run from Sep 30, 2023 through Sep 29, 2026. The Ohio State University has a history of conducting biomedical research and providing clinical trial coordination services to federal agencies like the National...
This $249,960 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by The Ohio State University to investigate the effects of the aged inflammatory central nervous system (CNS) microenvironment on oligodendroglial properties and remyelination capacity. The research aims to advance scientific understanding of age-related changes in the CNS that can impact myelin repair, with potential applications for...
This federal Project Grant award, valued at $826,875.00 and awarded by the Defense Health Agency on June 15, 2025, supports research on the "Novel Roles of SLIT2 in Enhancing Antitumor Immunity in Small Cell Lung Cancer" at The Ohio State University. This award falls under the Department of the Army Medical Command's Military Medical Research and Development (CFDA 12.420) federal grant program, which funds innovative biomedical research initiatives focused on transforming healthcare...
The Ohio State University received a $248,237 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award will fund a 3-year project from July 1, 2023 to June 30, 2026 to research and address traumatic brain injuries among law enforcement officers. No additional details about specific products or services to be delivered under this award were provided. The Military Medical Research and Development program supports basic,...
The Defense Health Agency awarded a $512,751.00 Project Grant to The Ohio State University for the period from July 1, 2023 to June 30, 2026. The grant was provided under the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform healthcare for Service Members and the American public through innovative and impactful research, and to investigate medical solutions for the battlefield. The grant funds will...
The federal Project Grant award of $1,225,245.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports a research initiative titled "CARDIOVASCULAR RISK PROFILING OF DEPLOYMENT-RELATED RESPIRATORY DISEASE: A TRANSLATIONAL APPROACH" at The Ohio State University. The research project aims to investigate cardiovascular risk factors associated with deployment-related respiratory diseases, with the goal of developing...
The Ohio State University received a $156,000 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program. The two-year award beginning in June 2021 will support research on Fatty Acid Binding Protein-5 as a novel therapeutic target against aggressive lung cancer. Through this funding, The Ohio State University researchers will investigate medical solutions for lung cancer, advancing the Military Medical Research...
The Department of the Army Medical Command awarded a $1,562,257 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to The Ohio State University for the project "TARGETING DE NOVO PYRIMIDINE SYNTHESIS TO TREAT OVARIAN CANCER." The 4-year grant, awarded on May 1, 2025, supports advanced biomedical research focused on investigating the role of pyrimidine synthesis in ovarian cancer progression and evaluating the therapeutic potential of inhibiting...